Laformin-G 1 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 1 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity. The combined action of these agents provides complementary mechanisms to effectively reduce blood glucose levels in patients inadequately controlled by diet and exercise alone. Laformin-G 1 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. It is important to monitor blood glucose levels regularly to adjust dosage and prevent hypoglycemia, a potential adverse effect primarily associated with Glimepiride. Contraindications include renal impairment, hepatic dysfunction, and conditions predisposing to lactic acidosis. Patients should be advised regarding signs of hypoglycemia and the importance of adherence to prescribed therapy. This medication should be used under medical supervision, with periodic assessment of renal function and glycemic status to optimize therapeutic outcomes and minimize risks.